Glucotrack Appoints Andy Balo to its Board of Directors

Retired Dexcom executive Andy Balo has joined Glucotrack Inc.’s Board of Directors.
 
Balo brings decades of regulatory, clinical and quality experience in the medical technology industry. In 2002 he joined Dexcom as part of the original executive team ,where he remained for the next 22 years playing a critical role in shaping the company’s future. During his tenure, he was responsible for numerous glucose monitoring regulatory submissions and clinical trials worldwide and coordinated quality activities across multiple manufacturing facilities. In March 2024, Balo retired from Dexcom as executive vice president of Clinical, Global Access, and Medical Affairs. Before he began working at Dexcom, Balo held several leadership positions at St. Jude Medical, including corporate vice president of Regulatory, Clinical, and Quality, and also served in executive roles at Baxter, Pacesetter, and Endocardial Solutions.

“We are honored to have Andy join our Board of Directors,” Glucotrack CEO Paul Goode, Ph.D., said. “He is nationally recognized as a thought leader in the regulatory and clinical landscape, and his experience in diabetes and cardiovascular technologies will be invaluable as we move into human clinical studies for our unique technology. Additionally, Andy is an authentic, driven and passionate leader who will help guide the company through our regulatory, clinical and commercialization milestones.”
 
Balo is widely regarded as an industry expert in regulatory and clinical strategies. He has served on several U.S. Food and Drug Administration panels as an industry representative, spanning cardiovascular, neurological, and gastrointestinal technologies. He has been instrumental in bringing several breakthrough medical devices to market, including continuous glucose monitors, tissue-based and mechanical heart valves, 3D electrophysiology mapping devices, pacemakers, and has obtained approval for more than 100 PMAs, PMA supplements, and 510ks.
 
Balo earned a bachelor of science degree in microbiology and chemistry from the University of Maryland and completed graduate studies at UCLA.
 
“I am excited to be joining the board of such an innovative and nimble medical technology company,” Balo stated. “Glucotrack’s continuous blood glucose monitor (CBGM) is a very compelling product that bridges diabetes and cardiovascular technology, leveraging established techniques and tools to create a truly differentiated glucose monitoring product. I look forward to working with the board and the leadership team to bring this technology to people living with diabetes every day.”
 
Glucotrack Inc. designs, develops, and commercializes technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of more than years, no on-body wearable component, and with minimal calibration.